GlassScriptPhysician profile
Joseph A Halpern
NPI 1164536447
$8,147.37
in general payments reported to CMS, 2019-2025
31 companies · $1,396 in 2025
The $1,396 reported for 2025 was more than what 96% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $600 · 2021: $1,511 · 2022: $1,388 · 2023: $1,472 · 2024: $1,190 · 2025: $1,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,058.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,958.94 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $950.76 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $868.11 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $605.56 | 2020-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $436.99 | 2021-2024 | |
| Biogen, INC. | $412.48 | 2020-2022 | |
| Pfizer INC. | $342.42 | 2019-2025 | |
| Lilly USA, LLC | $342.10 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $327.81 | 2019-2025 | |
| Abbvie INC. | $264.81 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $209.33 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $190.32 | 2023 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.79 | 2020-2023 | |
| Lundbeck LLC | $162.89 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.29 | 2025 | Caplyta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $95.06 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Radius Health, INC. | $91.05 | 2019 | |
| Astellas Pharma US INC | $86.85 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $74.97 | 2023-2025 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $67.17 | 2021 | |
| Corcept Therapeutics | $60.50 | 2024 | Korlym |
| Kowa Pharmaceuticals America, INC. | $52.16 | 2019 | |
| Amarin Pharma, INC. | $48.98 | 2021 | |
| Shield Therapeutics INC | $45.04 | 2022-2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $42.35 | 2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.84 | 2019 | |
| Ironwood Pharmaceuticals, INC | $24.18 | 2020-2021 | |
| Boston Scientific Corporation | $21.87 | 2020 | |
| Horizon Therapeutics Plc | $21.31 | 2023 | Krystexxa |
| Tms Neurohealth Centers INC. | $20.74 | 2025 | Tms Neurohealth Centers INC. |
| Neurocrine Biosciences, INC. | $17.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Halpern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.